EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and biological evaluation of novel pleuromutilin derivatives containing benzimidazoles as effective anti‐MRSA agents

Qi-Wen Zhang, Jie Ren, Jia-Xun Lu, Xiao-Ying Chen, Xian-Jin He, Qi Wang, Zi-Dan Zhou, Zhen Jin, Zhen-Ling Zeng, You-Zhi Tang iD

Drug Development Research · 2023

DOI: 10.1002/ddr.22095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Qi-Wen Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricu…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of pleuromutilin derivatives containing benzimidazole were designed, synthesized, and evaluated for their antibacterial activities against Methicillin‐resistant Staphylococcus aureus (MRSA) in this study. The in vitro antibacterial activities of the synthesized derivatives against four strains of S. aureus (MRSA ATCC 43300, S. aureus ATCC 29213, S. aureus 144, and S. aureus AD3) were determined by the broth dilution method. Among these derivatives, compound 58 exhibited superior in vitro antibacterial effect against MRSA (minimal inhibitory concentration [MIC] = 0.0625 μg/mL) than tiamulin (MIC = 0.5 μg/mL). Compound 58 possessed a faster bactericidal kinetic and a longer post‐antibiotic effect time against MRSA than tiamulin. Meanwhile, at 8 μg/mL concentration, compound 58 did not display obviously cytotoxic effect on the RAW 264.7 cells. In addition, compound 58 (−2.04 log 10 CFU/mL) displayed superior in vivo antibacterial efficacy than tiamulin (−1.02 log 10 CFU/mL) in reducing MRSA load in mice thigh infection model. In molecular docking study, compound 58 can successfully attach to the 50S ribosomal active site (the binding free energy is −8.11 kcal/mol). Therefore, compound 58 was a potential antibacterial candidate for combating MRSA infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusAnimalsMiceStaphylococcus aureusMolecular Docking SimulationStructure-Activity RelationshipAnti-Bacterial AgentsMicrobial Sensitivity TestsBenzimidazolesPleuromutilinsDiterpenes

Stichwörter der Autor:innen

MRSAantibacterial activitybenzimidazolemolecular dockingpleuromutilin

Substanzen

Anti-Bacterial AgentsBenzimidazolesPleuromutilinstiamulinDiterpenes

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
  • Guangdong Laboratory for Lingnan Modern Agriculture, Guangzhou, China.

ORCID-Profile: You-Zhi Tang

Zitieren

APA

Zhang, Q. W., Ren, J., Lu, J. X., Chen, X. Y., He, X. J., Wang, Q., Zhou, Z. D., Jin, Z., Zeng, Z. L., & Tang, Y. Z. (2023). Design, synthesis, and biological evaluation of novel pleuromutilin derivatives containing benzimidazoles as effective anti‐MRSA agents. Drug Development Research. https://doi.org/10.1002/ddr.22095

Vancouver

Zhang QW, Ren J, Lu JX, Chen XY, He XJ, Wang Q, et al. Design, synthesis, and biological evaluation of novel pleuromutilin derivatives containing benzimidazoles as effective anti‐MRSA agents. Drug Development Research. 2023. doi:10.1002/ddr.22095

BibTeX
@article{Zhang2023,
  author = {Zhang, Qi-Wen and Ren, Jie and Lu, Jia-Xun and Chen, Xiao-Ying and He, Xian-Jin and Wang, Qi and Zhou, Zi-Dan and Jin, Zhen and Zeng, Zhen-Ling and Tang, You-Zhi},
  title = {Design, synthesis, and biological evaluation of novel pleuromutilin derivatives containing benzimidazoles as effective anti‐MRSA agents},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22095}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche